Loading...
NPI 1174781231 · Hattiesburg, MS · Retina Specialist (Ophthalmology) Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Wright Lauten is a retina specialist (ophthalmology) physician provider located in Hattiesburg, Mississippi. This profile covers 24 Medicare and 17 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Wright Lauten |
| Address | 109 Millsaps Dr |
| City | Hattiesburg |
| State | MS |
| ZIP | 39402 |
| Taxonomy | Retina Specialist (Ophthalmology) Physician |
| NPI Enumerated | May 27, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $11.8M |
| Medicaid | $20.3K |
Practice model and service mix are retina-centric and injection-driven: Medicare billing is overwhelmingly dominated by intravitreal pharmacotherapy and retina diagnostics, with J2778 (ranibizumab injections), 67028 (isolated intravitreal injection), and 92014 (comprehensive established ophthalmology exam) identified as the top-revenue drivers. The code mix — heavy J2778 volume plus high-volume retinal imaging codes like 92134 and 92250 — is consistent with a high-throughput retina clinic that delivers frequent anti-VEGF injections alongside imaging-guided management and routine ophthalmic follow-up.
Extreme revenue concentration on a single therapy for Medicare: the precomputed top 3 Medicare codes account for 89.5% of this provider's Medicare revenue, and J2778 alone represents 79.7% of Medicare revenue. That concentration signals the practice’s financial exposure and operational focus on ranibizumab administration as the primary revenue stream.
Medicare competitive standing is dominant on key retina procedures: this provider ranks #1 nationally for J2778 (of 1208 providers) and #1 for 67028 (of 4255 providers), both listed at the 100th percentile and labeled extreme outlier, indicating far higher case volume than typical national peers. Additional retinal procedure and imaging codes — for example 92134 (rank #1 of 26868, 100th percentile) and 92250 (rank #16 of 25087, 100th percentile) — further support a national-level outlier profile in retina services.
Contrast with Medicaid scale and mix: Medicaid revenue is negligible compared with Medicare ($20.3K Medicaid vs $11.8M Medicare), so the provider functions effectively as Medicare-dominant for revenue. Medicaid billing is also concentrated: the top 3 Medicaid codes account for 96.0% of Medicaid revenue, led by 92134 (47.1%) and 67028 (40.1%), indicating the same clinical focus carries into the provider’s small Medicaid panel.
Differential drug utilization across Medicare: while J2778 (ranibizumab) is the primary anti-VEGF by revenue and volume, J0178 (aflibercept) is lower-volume and ranks at the 26th percentile, showing a notable preference or practice pattern favoring ranibizumab over alternative agents at this site. Bevacizumab (J9035) appears in Medicare billing at above-typical volume (97th percentile) but contributes a much smaller share of revenue compared with J2778, suggesting mixed agent use with ranibizumab dominant.
Operational implications for payers and networks: given the extreme concentration on intravitreal injections and imaging, networks assessing risk or capacity should treat this provider as a high-volume retina infusion/clinic site that will be sensitive to drug utilization policies, reimbursement changes for J2778, and capacity for same-day injections and imaging. The provider’s national outlier status on multiple retina codes implies substantial local market draw for retina patients, which may affect network adequacy and referral flows.
Tenure and market presence: the NPI was enumerated on 2008-05-27 (~18 years ago), indicating a long-standing presence in HATTIESBURG, MS; combined with the high procedure volumes and top national ranks, this tenure supports the interpretation of an established, high-throughput retina specialty practice.
Risk-profile nuance: although many retina procedural and imaging codes are extreme outliers nationally (100th percentile) and several procedures rank #1, some surgical retina codes and new-patient E/M visits (examples include selected vitrectomy and complex retinal repair codes) show typical or unremarkable national percentiles, suggesting the practice’s high volumes are concentrated in outpatient injections and imaging rather than extensive surgical retina case volume.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
24 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | 52,570 | $180 | $9.4M |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 9,160 | $90 | $843.1K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 3,790 | $80 | $310.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 4,900 | $60 | $304K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 8,660 | $30 | $242.6K |
| J0178 | Injection, aflibercept, 1 mg | 270 | $690 | $187.7K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 1,010 | $90 | $86.4K |
| J9035 | Injection, bevacizumab, 10 mg | 1,370 | $50 | $73.8K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 2,530 | $30 | $63.3K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 1,540 | $40 | $63.1K |
Showing 1–10 of 24
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
24 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J2778 | 1 | 10 | 1,300 | $180 | $1.3M |
| J0178 | 17 | 20 | 670 | $680 | $990.1K |
| 67028 | 1 | 30 | 600 | $80 | $107K |
| 67042 | 3 | 10 | 30 | $1,000 | $27.9K |
| 67036 | 14 | 10 | 20 | $890 | $25.7K |
| 92014 | 1 | 350 | 170 | $70 | $23K |
| 99214 | 970 | 4,110 | 170 | $70 | $21.9K |
| 67113 | 3 | 10 | 20 | $1,040 | $19.8K |
| J9035 | 1 | 10 | 210 | $50 | $18.1K |
| 92235 | 1 | 20 | 70 | $90 | $12.1K |
Showing 1–10 of 24
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 370 | $30 | $9.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 90 | $90 | $8.2K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 20 | $110 | $1.8K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 30 | $30 | $810 |
| 1036F | N/A | 500 | $0 | $0 |
| 2022F | The ophthalmology or optometry provider performs a dilated retinal eye exam in a diabetic patient with evidence of diabetic retinopathy. He interprets the findings and documents them in the patient’s… | 220 | $0 | $0 |
| 2024F | The ophthalmology or optometry provider takes photos of the eye in seven standard fields in a diabetic patient with evidence of diabetic retinopathy. He interprets the findings and documents them in… | 220 | $0 | $0 |
| 2026F | The ophthalmology or optometry provider uses other eye imaging to validate 7 standard field stereoscopic retinal photo results in a patient with diabetic retinopathy. He reviews and documents the… | 210 | $0 | $0 |
| 4040F | Pneumococcal vaccine triggers the immune response of the patient and protects against infection from pneumococcus bacteria, an infectious organism. The provider administers the vaccine to all… | 880 | $0 | $0 |
| 5010F | No Summary found for this code | 200 | $0 | $0 |
Showing 1–10 of 17
How this provider's Medicaid billing volume and revenue compare to other Mississippi providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Mississippi median
17 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J9035 | Injection, bevacizumab, 10 mg | 8 | 10 | 280 | $50 | $153.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 392 | 420 | 510 | $70 | $92.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 10 | 20 | 300 | $30 | $88.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 11 | 40 | 70 | $10 | $19.3K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 79 | 110 | 80 | $20 | $11.3K |
| 4040F | Pneumococcal vaccine triggers the immune response of the patient and protects against infection from pneumococcus bacteria, an infectious organism. The provider administers the vaccine to all… | 12 | 30 | 390 | $1 | $360 |
| 1036F | N/A | 71 | 180 | 280 | $1 | $340 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 15 | 30 | 150 | $1 | $190 |
| G8482 | Influenza immunization administered or previously received | 39 | 50 | 100 | $1 | $90 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 62 | 190 | 410 | $1 | $70 |
Showing 1–10 of 17
Other providers in the same ZIP code as Wright Lauten, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.